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Social anxietyThe ﬁrst study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social
anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic
individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses
that are common in this population. Serious Adverse Events (SAEs) involving the administration of MDMA in
clinical trials have been rare and non-life threatening. To date, MDMA has been administered to over 1133 indi-
viduals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited
reporting per FDA regulations. Now that safety parameters for limited use of MDMA in clinical settings have
been established, a case can be made to further develop MDMA-assisted therapeutic interventions that could
support autistic adults in increasing social adaptability among the typically developing population. As in the
case with classic hallucinogens and other psychedelic drugs, MDMA catalyzes shifts toward openness and intro-
spection that do not require ongoing administration to achieve lasting beneﬁts. This infrequent dosing mitigates
adverse event frequency and improves the risk/beneﬁt ratio of MDMA, which may provide a signiﬁcant advan-
tage over medications that require daily dosing. Consequently, clinicians could employ new treatment models
for social anxiety or similar types of distress administeringMDMA on one to several occasionswithin the context
of a supportive and integrative psychotherapy protocol.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The purpose of this paper is to provide an overview of the ratio-
nale and to summarize the method for a pilot study of 3,4-
methylenedioxymethamphetamine (MDMA)-assisted therapy for the
treatment of social anxiety in autistic adults.Multiple areas of investiga-
tion in autism research have paralleled MDMA research. Some
examples include neurobiological studies, particularly on the effects of
the neuropeptides oxytocin (OT) and vasopressin, which are believed
to play a role in interpersonal connection and bonding (Domes et al.,
2007a,2007b; Dumont et al., 2009; Hollander et al., 2003, 2007; Jacob
et al., 2007; Kirsch et al., 2005; Lerer et al., 2008; Sumnall, 2006), and
the neurotransmitter serotonin (Volkmar et al., 2009; Vollenweider
et al., 1998; Whitaker-Azmitia, 2005). Cognitive studies, such as inves-
tigations of themechanisms of face recognition, also appear in the liter-
ature of both autism (Adolphs et al., 2001; Ashwin et al., 2007, 2009;
Clark et al., 2008) and MDMA research (Hoshi et al., 2004).
Functional brain imaging studies with anxiogenic stimuli in autis-
tic individuals suggest that the amygdala may be differentially acti-
vated, with greater activation in the anterior cingulate gryus andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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left orbito-frontal cortex (Ashwin et al., 2007), or it may signal in an
atypical manner to the fusiform gyrus, a key brain region involved in
facial recognition, resulting in differences in social perception be-
tween autistic and typically developing (TD) individuals (Hall et al.,
2010). In TD healthy volunteers, MDMA administration acutely de-
creases activity in the left amygdala (Gamma et al., 2000), a brain re-
gion involved in the interpretation of negative cues, and attenuates
amygdalar response and emotional reactivity to angry faces (Bedi
et al., 2009). This action ofMDMA is compatiblewith its reported reduc-
tion in fear of emotional injury or defensiveness (Greer and Tolbert,
1986). The multi-level effects of MDMA on brain circuits, monoaminer-
gic neurotransmitters, and neurohormones that have been studied ex-
tensively in autistic individuals suggest that further study of the
effects of MDMA in autistic populations is warranted. In addition,
MDMA has been proposed as a treatment for anxiety disorders
(Johansen and Krebs, 2009), which are prevalent in autistic individuals
(Gillott and Standen, 2007). The current review takes into account
these areas of overlap and explores a parallel indication by studying
MDMA-assisted therapy as an intervention for social anxiety in autistic
adults.
1.1. Relevant history
MDMA, also known as the street drug Ecstasy or Molly, is a psycho-
active compound with structural similarities to both amphetamine and
the hallucinogenic phenethylamines (Grob and Poland, 1995).MDMA isTable 1
Major studies implicating the effects of MDMA.
Year Citation Sample Category
1986 Greer & Tolbert 29 Psychotherapy
1998 Grob 18 Phase 1 — Preliminary
2008 Bouso et al. 6 Psychotherapy
2011 Mithoefer et al. 20 Psychotherapy
2013 Mithoefer et al. 16 (CAPS);
19 (Questionnaire)
Psychotherapy (see abov
2013 Oehen et al. 12 Psychotherapy
2000 Gamma et al. 16 Mechanism of action
2009 Dumont et al. 15 Mechanism of action
2009 Bedi et al. 9 Mechanism of action
2014 Carhart-Harris et al. 19 Mechanism of action
2014 Bedi et al. 13 Mechanism of action
2014 Hysek et al. 32 Mechanism of action
2014 Kuypers et al. 20 Mechanism of action
2012 Hysek et al. 48 Mechanism of action
1996 Grob et al. 6 Pharmacodynamics/PK
1998 Vollenweider et al. 13 Pharmacodynamics/PK
2000 de la Torre et al. 14 (6 in study 1; 8 in study 2) Pharmacodynamics/PK
2001 Liechti and Vollenweider 16 Pharmacodynamics/PK
2001 Liechti et al. 74 (incl. earlier FXV samples) Pharmacodynamics/PK
2014 Kirkpatrick et al. 220a (contains de Wit,
ME Liechti data)
Pharmacodynamics/PK
2006 Mechan et al. 4 squirrel monkeys PK/risks and toxicity
2009 Rogers Review/meta analysis PK/risks
2007 Schilt 58 Ecstasy users, 60 controls PK/risks
2011 Halpern 52 Ecstasy users; 59 controls
matched for drug use
PK/Risks
2010 Nutt et al. 20 substances Risks/beneﬁts
2010 Van Amsterdam et al. 19 substances Risks/beneﬁts
2007 Sessa Review Therapy assessment
2009 Johanson and Krebs Review Review
a The Basel sample is not the same as the Zurich sample so the two sets represent independen
(Hysek–Liechti) team and at least of the Bedi/De Wit data (when collected at the University ofa laboratory-synthesized compound that does not exist on its own in
nature. Even though MDMA has been illegal in the United States since
the mid-1980s, there were 0.8 million past-year initiates who reported
ﬁrst-time Ecstasy use in 2013 (Substance Abuse and Mental Health
Services Administration, 2014).
MDMA was developed as a byproduct of a styptic compound at
Merck in Germany in 1912. University and industry based medicinal
chemists started conducting initial scientiﬁc investigations during the
1970s after chemist Alexander Shulgin began exploringMDMA's poten-
tial to create controllable altered states of consciousness. Despite report-
ed therapeutic potential (Greer and Tolbert, 1986; Grinspoon and
Bakalar, 1986), concerns about potential neurotoxicity resulted in sup-
pression of FDA-approved research with human subjects in clinical in-
vestigations. Gross errors in reporting on MDMA's effects, side effects,
and risk factors in non-human primate studies (e.g., Ricaurte et al.,
2003), in addition to problems with interspecies scaling algorithms
leading to overdosing by an order of magnitude in animal studies
(Baumann et al., 2007), have contributed to confusion about which
policies and approaches are optimal regarding regulation and research.
Early investigators notedMDMA's capacity to help people talk open-
ly and honestly about themselves and their relationships, without de-
fensive conditioning intervening (Greer and Tolbert, 1986; Stolaroff,
2004). For several hours, anxiety and fear appeared to decrease, even
in subjects who were chronically constricted and apprehensive. Of par-
ticular interest to psychiatric researchers were clients with disorders
such as chronic post-traumatic stress disorder (PTSD) and depression
who were nonresponsive to conventional treatment models. BeginningSigniﬁcance
First published report
Controlled study
Controlled study (incomplete)
Blinded, placebo controlled RCT
e) Long term follow up of above
2nd RCT, active placebo
PET study — b L amygdala
Elevated OT in an RCT
fMRI of brain — lower amygdala to angry faces
Worst memories less distressing & vivid
Increased social language RCT
Increased emotional empathy, prosocial in men
Plasma OT after MDMA unrelated to empathy
Changes in emotion reading, self-reported increased closeness, elevated OT
Reported cardiovascular, increased cortisol, prolactin
Subjective, cardiovascular, neuroendocrine & spont. reactions
Detected nonlinear pharmacokinetics
Using pretreatment studies, shows impact of 5HT release on MDMA effects
Pooled data — women report greater subjective effects & reactions, men
higher cardiovascular
Demonstrates similarity of MDMA effects across 3 independent laboratories
Detected nonlinear PK in monkeys, and demonstrates doses deemed
“human equivalent” weren't.
Systematic review and meta-analyses of literature concluding Ecstasy use may
produce signiﬁcant but small impairments and can but mostly won't be fatal
First prospective study of effects of Ecstasy use. Reported impaired
(actually less improvement) in verbal memory but no other areas.
Study strongly controlling for drug use histories and using low drug use sample.
Found few differences in cognitive performance save poorer strategic
self-regulation in Ecstasy users
Modeling determined alcohol, heroin most harmful; [magic] mushrooms,
buprenorphine last (i.e. least harmful); MDMA 17/20 on list.
Used similar team and produced similar but not identical rankings. In this model,
Ecstasy 14th of 19, rated slightly more harmful than Nutt et al.
Argues for use of MDMA in psychotherapy
Provides hypotheses and model for how MDMA might help treat anxiety
disorders
t data samples. However, Kirkpatrick et al.may cover data addressed in reports by the Basel
Chicago).
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MDMA to thousands of clients as an adjunct to therapy, but unfortu-
nately no methodical research was published from this period.
Formal hearings commenced in 1985 to determine MDMA's legal
status. Weighing the interests of the therapeutic community against
the growing perception of MDMA's abuse liability and the threat it
posed to public health and safety, the U.S. Drug Enforcement Adminis-
tration (DEA) eventually ordered that it be placed in themost restrictive
category, Schedule I, in 1986 (Lawn, 1986).
In the decades following the DEA scheduling, discord and divisive-
ness escalated in the research world. At the center of the debate was
the question of whether or not MDMA use caused neurotoxicity
resulting in brain damage. Histopathological ﬁndings in animal studies
with repeated “binge administration” injections demonstrated that dis-
tal serotonergic axonal degeneration could result with doses much
higher than recreational users consume (Sumnall, 2006). Implications
of such pre-clinical ﬁndings are further confounded by observations of
proximal axonal regeneration, cell body sparing, and absence of stan-
dard laboratory markers of neurotoxicity. Some studies suggested that
even modest use could lead to irreparable organic and psychiatric
damage, which included emotional and memory deﬁcits, although
these reports were often marred by ﬂawed research methodologies,
questionable data analyses, and biased conclusions (Danforth and
Grob, 2009; Grob, 2000, 2005; LeVay, 2008).
The Ecstasy user literature base also contains multiple factors that
limit the generalizability of naturalistic studies of street Ecstasy to clin-
ical settings in which pure MDMA is administered from one to several
times within a psychotherapy paradigm. The most substantial of these
limitations are the high quantities of doses taken in nearly all publica-
tions on recreational Ecstasy users, often on the order of several hun-
dreds of doses. Critics of MDMA-assisted psychotherapy use this data
to suggest a higher level of risk than logically can be inferred from no
more than six exposures reported in MDMA-assisted psychotherapy
clinical trials (e.g., Parrott, 2014). Additionally, “Ecstasy” refers to
MDMA obtained from street sources which currently is almost always
cut with other drugs as seized shipments from 2007 show only 3% of
tablets destined for North American markets containing pure MDMA
(Hudson et al., 2014) (https://www.ecstasydata.org/stats.php). Authors
commonly cite Ecstasy user data and use it to draw conclusions about
MDMAwithout citing the above purity limitation (Grob, 2000). Further-
more, Ecstasy users are also almost always polysubstance abusers as in-
dicated in the 2007 National Epidemiologic Survey on Alcohol and Related
Conditions (n = 43,093) (Wu et al., 2009), and high polysubstance
abuse rates confound nearly all of the Ecstasy correlations found in the
medical literature to date. Other common notable hazards include ad-
verse environmental conditions, polydrug use in dangerous combina-
tions, and ingestion of high doses or stacking multiple doses to
prolong drug effects. Therefore, research on recreational Ecstasy use
has limited applicability to determining the safety of clinical investiga-
tions of MDMA-assisted therapy.1.2. Pharmacology and behavioral effects in animals
Research into the pharmacological, physiological, or psychological
effects of MDMA began in the 1950s, when the U.S. Army administered
MDMA to guinea pigs,monkeys,mice, rats, and dogs as part of amilitary
research program, possibly intended to develop chemical incapacitants
or means of enhancing interrogation (Hardman et al., 1973). Investiga-
tions of the pharmacology, functional effects, and toxicity of MDMA in
animals have generally included injections of large and often repeated
doses of MDMA in an attempt to produce human-equivalent doses
(Baggott et al, 2001). Recent reports re-examining these effects have
questioned the applicability of interspecies scaling models for MDMA,
and have supported nonlinear pharmacology (Baumann et al., 2009;
Mechan et al., 2006; Wang et al., 2005).A study directly comparingMDMApharmacokinetics in humans and
monkeys found that the two speciesmetabolizedMDMA in a similar but
not identical manner and thatMDMA had a shorter half-life inmonkeys
than in humans. Both species exhibited nonlinear pharmacokinetics,
and it appears that monkeys and humans exhibit similar plasma
MDMA levels after receiving the same dose of MDMA (Mueller et al.,
2009a,2009b). An investigation in rats also demonstrated nonlinear
pharmacokinetics in that species as well, ﬁnding that human-
equivalent doses of MDMA in rats are close to or identical to those in
humans and drug half-life is rapid (Baumann et al., 2009). Doses of
10 mg/kg, but not 2 mg/kg, produced signs of serotonin syndrome in
rats, but neither dose reduced total serotonin levels in the brain two
weeks after drug administration. These discoveries suggest that toxico-
logical and behavioral studies of MDMA used doses exceeding human
equivalent doses. As a consequence, it is difﬁcult to interpret the rele-
vance of ﬁndings in nonclinical studies employing these dosing regimes.
Early studies in rodents suggest that 5HT1A receptors reduce anxiety
and aggression (Brunner and Hen, 1997; Graeff et al., 1996), and some
drug discrimination studies suggest that the 5HT1A agonist 8-OH-
DPAT partially or fully substitutes for MDMA (Glennon and Young,
2000; Glennon et al., 2007; Schechter, 1986). Administering a 5HT1A an-
tagonist attenuates the prosocial behavior of rats, measured by prefer-
ence to lie adjacent to each other, possibly because it prevents
elevation in OT (Morley et al., 2005; Thompson et al., 2007). At least
some direct or indirect effects of MDMA on serotonin receptors may
cause changes in GABA uptake in the ventral tegmental area of rats
(Bankson and Yamamoto, 2004). In rodents, doses of MDMA equivalent
to human doses produce either few or no behavioral effects. However,
doses of 5 mg/kg or greater have several speciﬁc behavioral effects, in-
cluding increased locomotor activity, increased anxiety at moderately
high doses, and decreased anxiety at higher doses (Cole and Sumnall,
2003; Green et al., 2003). In contrast, rhesusmonkeys do not exhibit in-
creased locomotor activity after receiving up to 2.4 mg/kg MDMA
(Crean et al., 2006).
To date, no empirical investigations have been conducted on the ef-
fects of MDMA on primate social interactions. Morley and colleagues
observed rat behavior after receiving 5 mg/kg MDMA, noting that this
dose correlated with prosocial behavior, such as lying next to each
other (Morley et al., 2005). Recent studies conducted by the same
team of researchers suggest that MDMA increases prosocial behavior
in rats by elevatingOT in the paraventricular nucleus through 5HT1A re-
ceptor agonism, with the OT increase arising from the indirect effects of
MDMA on 5HT1A receptors (Thompson et al., 2007, 2009). At present,
there have been no human pharmacological challenge studies combin-
ingMDMAwith 5HT1A agonists, while 5HT1A antagonists have negligi-
ble effects on subjective or physiological effects of MDMA in humans
(Hasler et al., 2009; Hysek et al., 2010; vanWel et al., 2012). As a result,
it is unclear whether the rat behavior is analogous to human reports of
increased feelings of empathy or interpersonal closeness while under
the inﬂuence of MDMA (Liester et al., 1992; Peroutka et al., 1988;
Solowij et al., 1992; Vollenweider et al., 1998).
1.3. Summary of effects of MDMA in humans
MDMA is primarily a potent releaser of serotonin aswell as an inhib-
itor of presynaptic serotonin, dopamine, and norepinephrine (de la
Torre et al., 2004). Pharmacologically it exhibits effects similar to am-
phetamine type drugs, with a chemical structure that also resembles
the classic hallucinogen mescaline. The primary mode of action of
MDMA is as an indirect serotonergic agonist, increasing the amount of
serotonin released into the synaptic space. MDMA interacts with the se-
rotonin transporter, and is transported into the nerve terminal, facilitat-
ing the release of serotonin. After oral ingestion, MDMA is readily
absorbed from the gastrointestinal tract.
At doses of at least 1 mg/kg (or approximately 70 mg) and higher,
active doses of MDMA alter mood and cognition and produce slight
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2001). Its onset of action is within 30–45 min of intake, and effects
peak 90 to 120 min after oral administration, and they are near to or
at pre-drug levels 3 to 6 h later (Lamers et al., 2003; Tancer and
Johanson, 2001; Vollenweider, 1998). Sub-acute effects may occur one
to three days after drug administration, but are no longer apparent
seven to 14 days later (Harris et al., 2002; Huxster et al., 2006; Pirona
and Morgan, 2010). The elimination half-life is approximately 7 h.
MDMA's primary metabolite, 3-4 methylenedioxyamphetamine
(MDA), has a longer half-life of approximately 16–38 h. Primary enzy-
matic activity responsible for the metabolism of MDMA occurs at the
hepatic cytochrome P45 CYP2D6 enzyme. MDMA is metabolized in a
non-linear manner with relatively small increases in dose causing dis-
proportionate elevation in MDMA plasma concentration, consequently
necessitating vigilance for the development of signs of acute adverse re-
actions (Harris et al., 2002; Mas et al., 1999).
1.3.1. Physiological effects
MDMA acutely increases cortisol, prolactin, and adrenocorticotropic
hormone concentrations in a dose-dependent manner (Farré et al.,
2004; Grob et al., 1996; Harris et al., 2002; Mas et al., 1999; Parrott
et al., 2008). MDMA also produces a robust increase in the neurohor-
mone OT (Dumont et al., 2009). OT is a neuropeptide associated with
pair bonding and social afﬁliation in mammals that also attenuates
amygdalar response to anxiogenic stimuli (Adolphs et al., 2005; Bartz
and Hollander, 2006). Exogenous OT administration is associated with
increased interpersonal trust and changes in social perception, includ-
ing attenuated reactivity to threatening faces (Domes et al., 2007a,
2007b; Kosfeld et al., 2005). OT administration also improves empathic
accuracy in some individuals who are shy or lack adequate social skills
(Guastella et al., 2010). Alterations in OT signaling have also been pro-
posed as a potential mechanism for the underlying neurological basis
for the core social differences in autism and have been implicated as a
possible novel therapy for enhancing social adaptability (Bartz and
Hollander, 2006).
MDMA elevates OT in peripheral blood (Dumont et al., 2009; Hysek
et al., 2012; Wolff et al., 2006), which is an imperfect but somewhat re-
liable indicator of elevated OT in the brain (Bartz and Hollander, 2006).
Findings of an association between elevated OT and detectable MDMA
in peripheral blood were ﬁrst reported in a naturalistic study of
London nightclub attendees with and without detectable plasma
MDMA levels (Wolff et al., 2006). Dumont and colleagues reproduced
these results in humans and found that MDMA signiﬁcantly elevated
peripheral plasma OT levels in a placebo-controlled study in healthy
volunteers (Dumont et al., 2009), in addition to a positive association
between elevated levels of OT and prosocial feelings. Hysek and col-
leagues replicated these results and further reported that administering
a serotonin reuptake inhibitor, but not a norepinephrine uptake inhibi-
tor nor several adrenergic antagonists, attenuated the effects of MDMA
on OT levels, suggesting a serotonergic mechanism in producing elevat-
ed (Hysek et al., 2012). The effects ofMDMA onOT could be partially re-
sponsible for changes in empathy (Bedi et al, 2010). However, the
multi-level effects of MDMA on monoaminergic signaling and OT,
combined with a therapeutic setting focused on enhancing functional
skills, are more likely to provide the opportunity for a corrective
emotional experience greater than OT alone, and could be useful in
the treatment of social anxiety in autistic adults.
Hyperthermia has occurred in people using Ecstasy in unsupervised
and non-medical conditions (e.g., vigorous dancing in hot,
underventilated spaces without adequate access to water), and though
rare, it is one of the most frequently reported SAEs occurring in Ecstasy
users (Henry and Rella, 2001; Liechti et al., 2005). In rare but sometimes
lethal cases, naïve users have consumed too much water without
ingesting required amounts of electrolytes, leading to water intoxica-
tion (hyponatremia) (Milroy, 2011). Taking MDMA with monoamine
oxidase inhibitors (MAOIs) or with certain antiretroviral medicationscan induce a life-threatening hypertensive crisis (Harrington et al.,
1999; Smilkstein et al., 1987).
MDMA produces sympathomimetic effects that include elevation in
blood pressure and heart rate. Elevation in blood pressure above 140/
110 or higher occurred in approximately 5% of research participants re-
ceiving at least 100mgMDMA in research studies. However, blood pres-
sure returned to normal as drug effects waned (Downing, 1986; Grob,
1998; Grob et al., 1996; Lester et al., 2000; Liechti et al., 2001; Mas
et al., 1999; Vollenweider et al., 1998). The elevation of blood pressure
and increased heart rate produced by MDMA, like that produced by
other sympathomimetic drugs, can lead to additional risks and compli-
cations (Hughes et al., 1993; Kaku and Lowenstein, 1990; Perez et al.,
1999), such as stroke, cardiac events or other cerebrovascular events,
including cerebral venous sinus thrombosis (Rothwell and Grant,
1993) and cerebral hemorrhage (Gledhill et al., 1993; Henry et al.,
1992; Manchanda and Connolly, 1993; Selmi et al., 1995). First-time
users with congenital heart defects are especially vulnerable to cardiac
events (Hall and Henry, 2006). Due to properly conducted medical
screening, there have been no such events to date in any clinical trial
of MDMA.
Some researchers expressed concern that MDMA activity at 5HT2B
receptorsmight be indicative of increasing risk of valvular heart disease
(VHD) with repeated use (Setola et al., 2003). Studies in Ecstasy users
indicated that only people reporting average lifetime exposure of 900
tablets had cardiac abnormalities indicative of potential VHD
(Droogmans et al., 2007), and a case of VHD has occurred in a man
reporting approximately 16 years of Ecstasy use (Montastruc et al.,
2012). No abnormalities were found in people reporting lifetime expo-
sure of approximately 200 tablets in the same study. Since VHD-
associated changes and VHDonly occurred after extremely heavy Ecsta-
sy use, they are unlikely to be a risk within the research or therapeutic
context.
Hepatotoxicity (liver disease or damage) was reported in approxi-
mately 16% of 199 case reports from non-medical, uncontrolled Ecstasy
users, making it the third most SAE reported in the literature (Baggott
et al., 2001). No cases of liver disease or hepatotoxicity have occurred
in a controlled clinical trial with MDMA.
MDMA is not considered physically addictive, but there have been
reports of both acute and chronic psychological reactions in vulnerable
individuals (Parrott, 2007). Nevertheless, these cases generally have
been in the context of frequent polydrug use, Ecstasy or Molly use of
dubious quality, adverse environmental settings, and signiﬁcant under-
lying psychological vulnerability (Grob, 2005). Even though Ecstasy is
considered a drug of abuse, pure MDMA is not considered a drug of de-
pendence on the order of opioids, amphetamines, methamphetamines,
and cocaine. This lack of dependence is evidenced by rodents and non-
human primates self-administering MDMA at much lower rates than
the aforementioned drugs (De La Garza et al., 2007; Schenk, 2009),
and even heavy Ecstasy users fail to report the intensive patterns of
use seen with other stimulants. Hence, MDMA possesses moderate
abuse liability that is greater than that for serotonergic hallucinogens
but less than that for stimulants. Nutt et al. (2010) have studied the rel-
ative harm of a variety of drugs and have identiﬁed MDMA as being
among the least dangerous recreational compounds.
1.3.2. Neuropsychological effects
Most of the therapeutic effects of MDMA result from changes in af-
fect, cognition and social interaction. Vollenweider et al., (1998) report-
ed thatMDMAproduced acute “increased responsiveness to emotions, a
heightened openness, and a sense of closeness to other people” (p. 247).
When combined with psychotherapy that supports one or more of
these effects, MDMA permits individuals to confront and consider emo-
tionally intense memories, thoughts or feelings and perhaps through
changes in mood and perception increases empathy and compassion
for others and one's self (Bouso et al., 2008; Greer and Tolbert, 1986;
Mithoefer et al., 2011).
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(Camí et al., 2000; Harris et al., 2002; Liechti et al., 2001; Tancer &
Johanson, 2001).MDMAusers report feelingmore talkative and friendly
after receivingMDMA, and at least one research team informally report-
ed increased feelings of closeness to others (Vollenweider et al., 1998).
However, subjects have also reported feeling anxious and undergoing
negatively experienced derealization, including increased anxiety relat-
ed to loss of control and experiences of racing or blocked thoughts
(Camí et al., 2000; Liechti et al., 2001; Vollenweider et al., 1998). Sub-
jects receiving active doses of MDMA experienced euphoria, positive
mood, vigor and positively experienced derealization, and they also ex-
perienced anxiety, tension and dysphoria, as concern over losing control
over the self (Camí et al., 2000; Harris et al., 2002; Tancer & Johanson,
2001; Liechti et al., 2001). Available data is unclear regarding whether
the increases in positive and negative mood occur simultaneously or
occur at different times throughout the duration of MDMA effects;
data in reports from two different teams suggest that peaks in negative
mood may precede peaks for positive mood (Tancer & Johanson 2001;
Liechti and Vollenweider, 2000). Table 1 lists major studies implicating
the effects of MDMA.
1.4. Clinical advantages of MDMA
As a clinical intervention to increase social adaptability, MDMA pro-
vides speciﬁc advantages. In supportive settings, a typical oral dose of
75–125 mg produces psychological effects that are distinct from those
of classic hallucinogens (Nichols, 1986; Vollenweider et al., 1998).
Beginning in the late 1970s, proponents saw the beneﬁts of MDMA,
compared to classic hallucinogens, making it uniquely suited as an ad-
junct to therapy. It was comparatively mild, shorter acting, and induced
an enhanced ability to facilitate heightened states of introspection, all
without distracting cognitive distortions and alterations in perception,
body image, and sense of self commonly seen with classic hallucino-
gens, such as LSD, psilocybin, andmescaline. Userswere reported as los-
ing defensive anxiety and feeling more emotionally open thus giving
them access to feelings and thoughts not ordinarily available to them.
In informal settings, MDMA was reported to be useful in treating a
wide range of conditions, including post-traumatic stress, phobias, psy-
chosomatic disorders, depression, suicidality, drug addiction, relation-
ship difﬁculties and the psychological distress of terminal illness
(Adamson and Metzner, 1988; Downing, 1986; Greer and Tolbert,
1986; Grinspoon and Bakalar, 1986; Riedlinger and Riedlinger, 1994).
Lasting improvementwas often reported in patients' self-esteem, ability
to communicatewith signiﬁcant others, capacity for achieving empathic
rapport, interest in and capacity for insight, strengthened capacity for
trust and intimacy, and enhanced therapeutic alliance (Grinspoon and
Bakalar, 1986).
2. Phase 1 and Phase 2 clinical studies with MDMA
2.1. Establishing safety and feasibility
Recent research with human subjects has focused on establishing
safety parameters for limited use of MDMA-assisted therapy in U.S.
and European clinical settings (e.g., Mithoefer et al., 2011, 2013;
Oehen et al., 2013). The ﬁrst double-blind, placebo controlled U.S.
Phase 1, FDA-compliant study was conducted in 1994, with ﬁndings
that suggested MDMA may cause a statistically signiﬁcant increase in
body temperature, heart rate, and blood pressure in some healthy vol-
unteers (Grob, 1998; Grob et al., 1996; Lieb et al., 2002). However,
these increases were found to be transient and generally tolerable in a
controlled clinical setting. Subsequent trials conﬁrmed thatMDMA pro-
duced signiﬁcant increases in heart rate and blood pressure that were
likely to be well tolerated by healthy individuals (Check, 2004; Doblin,
2002; Hysek et al., 2012; Lieb et al., 2002; von Sydow et al., 2002). As
of November 2014, MDMA had been administered to more than 1133research subjects, in both Phase 1 and Phase 2 studies. Only one expect-
ed SAE thatwas probably drug-related has been reported, whichwas an
increase in frequency of premature ventricular contractions experi-
enced during treatment, which resolved with full recovery to baseline
after the effects of MDMA ceased. No acute cardiac damage occurred,
and hospitalization during this SAEwas a cautionarymeasure. No unex-
pected, life-threatening SAEs have occurred in published or ongoing re-
search studies (Jerome and Baggott, 2003;Multidisciplinary Association
for Psychedelic Studies, 2015)
2.2. MDMA-assisted therapy for PTSD
The ﬁrst placebo-controlled Phase 2 pilot study of MDMA-assisted
psychotherapy for the treatment of chronic, treatment resistant PTSD
demonstrated promising results in a sample of 20 subjects (Mithoefer
et al., 2011). Scores on the Clinician-Administered PTSD Scale (CAPS),
an established gold-standard measure of PTSD symptoms, declined to
a statistically and clinically signiﬁcant degree after undergoing
MDMA-assisted psychotherapy. The group of subjects randomized to
receive MDMA showed a mean CAPS score reduction of 53.7, with a
mean starting score of 79.2, whereas, participants in the placebo arm
who also received psychotherapy had a mean starting score of 79.6
and showed amean CAPS score reduction of 20.5. As a point of compar-
ison, a reduction of mean CAPS scores of 10.2 in a clinical trial of 187 pa-
tients resulted in FDA-approval of sertraline (Zoloft) for PTSD (Brady
et al., 2000). Improvements in PTSD symptoms observed in the proof
of principle study were maintained an average of 3.8 years later (N =
16) (Mithoefer et al., 2013). Mithoefer et al., (2011) reported that,
“MDMA-assisted psychotherapy with close follow-up monitoring and
support can be used with acceptable and short-lived side effects in a
carefully screened group of subjects with chronic, treatment-resistant
PTSD” (p. 449). A double blind pilot study of MDMA-assisted psycho-
therapy conducted by a Swiss therapist team in an equivalent Swiss
clinical population (N = 12) comparing 125 mg MDMA to 25 mg
MDMA as an active placebo found a clinically but not statistically signif-
icant effect, although trends toward symptomatic improvement were
noted using a German translation of the CAPS (Oehen et al., 2013).
The improvement continued to increase during the twelve-month
follow-up.
Currently, four Phase 2 pilot studies of MDMA-assisted psychother-
apy are underway for treatment of chronic PTSD (NCT01689740,
NCT01793610, NCT01211405, NCT01958593), including one in trauma-
tizedwar veterans and aswell as ﬁrst responders, such as police ofﬁcers
and ﬁre ﬁghters. These studies have shown promise forMDMA-assisted
psychotherapy to help people overcome PTSD, an anxiety-related disor-
der, and suggest that this treatment could also be useful in treating so-
cial anxiety in autistic adults.
3. The need for innovative mental healthcare options for autistic
adults
Amajor revision of autismdiagnostic criteria in the in the Diagnostic
and Statistical Manual of Mental Disorders, 5th edition (American
Psychiatric Association, 2013) eliminated the distinctions between au-
tism categories and combined them under one diagnosis. The revised
DSM-5 deﬁnition includes the former diagnoses of Asperger's Disorder
and Pervasive Developmental Disorder. The term autism refers to a
spectrum of congenital and pervasive neurocognitive variants, charac-
terized, in part, by atypical development of social and communication
skills.
At present, there are no published research data in support of any
compound that can inﬂuence the course of autism or be a causative
agent. Autistic adults often present for treatment of conditions such as
anxiety, trauma, depression, and social adaptability challenges. Howev-
er, responses to conventional prescription medications evaluated in TD
individuals are often ineffective in autistic individuals (e.g., King et al.,
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clinicians and clients can interfere with conventional, psychodynamic
psychotherapy (Koenig and Levine, 2011; Ramsay et al., 2005). The
search for new supportive treatments is relevant given the lack of
established or effective treatment options for anxiety, depression, trau-
ma, and other psychological distress in autistic adults.
3.1. Pharmacotherapy: few effective options
Clinical diagnoses such as anxiety disorders, depression, obsessive–
compulsive disorder, Tourette's syndrome, tics, and epilepsy are com-
mon in autistic populations (Barnhill and Myles, 2001; Canitano and
Vivanti, 2007; Cath et al., 2008; Duggal et al., 2001; Frazier et al.,
2002; Newman and Ghaziuddin, 2008; Saulnier and Volkmar, 2007;
Tsai, 2006;Wymbs et al., 2005). Conventional anti-anxietymedications,
including selective serotonin reuptake inhibitors (SSRIs), MAOIs, and
benzodiazepines, lack substantial clinical effectiveness in autistic adults,
potentially due to physiological differences between autistic and TD
individuals. There may be underlying biological reasons for this differ-
ence, including some reported evidence for a lower number of benzodi-
azepine binding sites in the brains of autistic adults (King et al., 2009;
Oblak et al., 2012).
Medications approved for the treatment of other indications are
often prescribed “off-label” without the Food and Drug Administration
(FDA) approval for the use in autistic children, adolescents, and adults.
For example, off-label prescription of SSRIs is on the rise in this popula-
tion (Hollander et al., 2012). The data on SSRIs in the treatment of autis-
tic individuals are of varied nature. Given the paucity of conﬁrmed
efﬁcacy in clinical trials and clinical practice, the search for effective,
complementary and alternative interventions for mental health issues
in autistic populations remains urgent.
3.2. Social anxiety and autism
Social anxiety, also known as social phobia, is characterized by fear
of scrutiny and avoidance of social interactions (American Psychiatric
Association, 2013). Social anxiety is prevalent (Kessler et al., 1994), be-
gins early (Hazen and Stein, 1995; Öst, 1987), and follows a chronic
course (Reich et al., 1994). Impairment is substantial in TD individuals
(Schneier et al., 1994), and fear and avoidance behaviors interfere
with ability to work, attend school, and develop relationships, leading
to low quality of life (Liebowitz et al., 1985; Turner et al., 1986).
Comparative studies suggest that autistic adults, especially those
who can speak and whose autism might not be immediately recogniz-
able to others and who are faced with strong pressure to conform to
non-autistic social norms, are at greater risk for lifetime and current
psychological disorders, especially social anxiety (Joshi et al., 2012;
Tantam, 1991, 2000). Social anxiety frequently compounds the consid-
erable social challenges experienced by autistic adults (White et al.,
2010).
4. Factors in support of MDMA-assisted therapy for social anxiety in
autistic adults
The primary purpose of this paper is to provide an overview of
three main factors that supported the rationale for commencing
the ﬁrst pilot study of an MDMA-assisted therapy treatment model
for an adult autistic population. The ﬁrst factor is clinical ﬁndings
in reports from early research with psychedelics in studies with
autistic minors. The second factor is improved methodology
for conducting safe and ethical research with psychedelics and
MDMA, especially in vulnerable populations. The third, and most
recently available, factor in support of commencing a pilot study is
copious anecdotal support culled from public sources and scholarly
exploratory inquiry.4.1. Early psychedelics research with autistic minors
Psychedelics are a large class of natural and synthetic substances
with limited abuse liability and psychoactive properties that alter
thought, mood, and perception in characteristic ways that can resemble
dreaming, psychoses, and ecstatic religious experiences. The term is
often used synonymously with hallucinogens in the medical literature.
However, with psychedelics, the perceiver retains awareness of the illu-
sory and personal nature of the altered perceptions (Aleman and de
Haan, 1998). MDMA is difﬁcult to classify because it causes fewer and
attenuated hallucinogenic effects (Nichols, 1986) with less cognitive
distortion (Grinspoon and Bakalar, 1986) than other classes of psyche-
delics. MDMA also has mild to moderate amphetamine-like effects
and produces subjective prosocial effects which are distinct from the
mysticospiritual effects of the classic hallucinogens. Whereas MDMA
and classic hallucinogens have different neurobiological mechanisms
of action, they share similar psychological effects of catalyzing states
of openness and introspection. Therefore, a review of prior research
with classic hallucinogens with autistic minors is relevant to a discus-
sion of MDMA-assisted therapy for autistic adults with social anxiety.
From the late 1950s to the early 1970s, researchers in the United
States, Europe and Argentina (e.g., Abramson, 1960; Bender et al.,
1962, 1963; Fisher and Castile, 1963; Freedman et al., 1961; Simmons
et al., 1972, 1966) experimented with therapeutic applications of syn-
thetic psychedelic compounds, mainly LSD, UML (a methylated deriva-
tive of LSD), and psilocybin, in attempts to “treat” autistic children
during an era when autism was mistakenly considered a form of
juvenile schizophrenia until clinical interest declined when funding
for research and access to psychedelics decreased due to illicit use and
political pressure (Sigafoos et al., 2007). Whereas giving powerful psy-
chedelics to distressed, non-speaking children seems inappropriate ac-
cording to current ethics and safety standards, in the 1950s and 1960s,
synthetic psychedelics were considered new and novel medications
with a favorable safety proﬁle that held promise for treating, what
were considered at the time, autistic-type developmental disorders in
youth.
Researchers shared the common goal of breaking throughwhat they
interpreted as the “autistic barrier” toward increased empathic affect
and attachment in the absence of effective interventions for behaviors
such as self-harm (Mogar and Aldrich, 1969). However, the rationales
for conducting the research varied. Some studies emphasized a medical
approach. For example, the prospect of restoring speech as a means to
reduce isolation inspired some investigators after case reports were
published on catatonic schizophrenic adults who were electively mute
at baseline but who spoke while under the effects of LSD (Cholden
et al., 1955; Freedman et al., 1961). Employing a neurobiological ap-
proach, Bender et al., (1963) made early attempts to understand the
role of the neurotransmitter serotonin by including biochemical tests
in LSD study protocols.
Other researchers emphasized subjective considerations. Fisher
(1970), for example, took a psychodynamic approach when providing
LSD and psilocybin to autistic children. Fisher emphasized the potential
of psychedelics to augment the psychotherapeutic alliance: “Little of
what may be called health or growth can occur without legitimate
and honest relationships between people. The drugs were, however,
in our judgment, of extreme importance inmaking thepsychotherapeu-
tic experience” (p. 112).
From 1959 to 1970, more than 100 minors with the obsolete diagno-
sis of juvenile schizophrenia, autistic type or similar descriptions were
given psychedelics in approximately a dozen trials of varying sizes and
durations. In at least six studies, children as young as ﬁve years old
were given repeated moderate to high doses (100–300 μg) of LSD
(e.g., Abramson, 1960; Fisher, 1970; Simmons et al., 1972). In retrospect,
themethods employedwere ﬂawed to varying degrees according to cur-
rent standards, including: small sample size (e.g., Rojas-Bermúdez, 1960;
Rolo et al., 1965; Simmons et al., 1966), vague and subjective assessment
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Freedman et al., 1961; Rolo et al., 1965), absent or incomplete baseline
data (e.g., Bender et al., 1963; Rojas-Bermúdez, 1960), and inadequate
follow-up data collection (Mogar and Aldrich, 1969). A majority of the
early researchers were primarily concerned with observing drug effects
and proceeded without a clearly stated treatment hypothesis or random
assignment to control groups, and reports on the persistence of post-
session effects were vague and inconsistent.
Mogar and Aldrich (1969) published a comprehensive review of
seven independent studies of LSD for treatment of emotional distress
and social isolation in 91 autistic children (Abramson, 1960; Bender
et al., 1962, 1963; Fisher and Castile, 1963; Freedman et al., 1961; Rolo
et al., 1965; Simmons et al., 1966). Despite “gross shortcomings”
(Mogar and Aldrich, 1969, p. 5) and inconsistencies across the seven
studies, the reviewers concluded that there was general consensus
among the research teams that the LSD treatment sessions were “effec-
tive in characteristic ways,” (p. 1) including increased vocabulary,
increased emotional responsiveness to others, an elevation in positive
mood, and decreases in compulsive behavior (p. 13). Social behaviors,
such as eye-to-face contact and engagingwith the researchers, were ob-
served more frequently during LSD sessions than in placebo or control
sessions. No researchers reported serious side effects, toxicity, or per-
manent regression following treatment with psychedelics.
The general consensus resulting from the early research was that
psychedelics were unlikely to restore speech in non-speaking autistic
children. However, most researchers concluded that psychedelics
allowed subjects a greater degree of contact with others, regardless of
demographics, dose, schedule, or setting (Mogar and Aldrich, 1969).
Nevertheless, the Controlled Substances Act of 1970 resulted in an
abrupt cessation of virtually all clinical research with psychedelic
compounds.
The diagnostic distinctions for less readily apparent manifestations
of autism have emerged over the past several decades (Volkmar et al.,
1994; Wing, 1981) but were not recognized in the research literature
until well after clinical research with psychedelics had ended. Now
that research with psychedelic-assisted therapy to promote social
adaptability is resuming, investigators can recruit autistic adults who
speak or who use text-to-speech technology instead of working with
non-speaking children. In the early studies, investigators could not
collect self-reported baseline or follow-up data, conduct interviews,
conﬁrm informed assent, or communicate verballywith subjects during
most experimental psychedelic treatment sessions.
4.2. Improved methods and standards for psychedelic research
Few, if any, of the clinical studies conducted with psychedelics be-
tween the 1950s and early 1970s would satisfy current design, safety,
and ethics requirements for research with human subjects. Among nu-
merous serious shortcomings,most early psychedelic trials lacked rigor-
ous oversight by institutional review boards, adequate data and safety
monitoring, or adherence to current best practices for scientiﬁc research
(e.g., adequate informed consent, random assignment to placebo con-
trol groups, double-blinded dosing regimens). Due to restrictions on re-
search using psychedelics with human subjects and the ﬂawed
methodology of earlier trials, researchers have had few resources to
consult regarding the best methods for optimizing safety during chal-
lenging psychedelic experiences. However, guidelines and suggestions
for improvements in clinical studies and psychotherapy with psyche-
delics have been published by reputable investigators and are available
to inform new research (e.g., Greer and Tolbert, 1998; Johnson et al.,
2008; Richards et al., 1972; Strassman, 1995; Winkelman & Roberts,
2007).
A signiﬁcant innovation in support of resuming clinical research
with psychedelics is the evolved understanding of the importance of
set and setting. In psychedelic therapy, set refers to the traits, mind
state, and expectations of the subject regarding the session(Strassman, 1995). Grof (1980) also considered the psychotherapist's
perception of the nature of the experience, the preparation and pre-
session psychotherapy, and the speciﬁc technique of guidance
employed during the drug experience as contributing to set. Setting
refers primarily to the external factors that inﬂuence the ambiance of
the experience for the client. For an ideal setting, Grof (1980) recom-
mended a safe and pleasant environment plus reassuring and nurturing
interpersonal support.
4.3. First-person reports of MDMA/Ecstasy use by autistic adults
The introduction of the Internet has provided new and effective
means for autistic individuals to communicate with others who are
both autistic and non-autistic, often with greater ease than in face-to-
face situations (Davidson, 2008). Ample anecdotal data regarding the
MDMA/Ecstasy experiences of autistic individuals available through
spontaneous, ﬁrst-person accounts posted in online discussion forums
provided foundational support for clinical research on MDMA-assisted
therapy for social anxiety with autistic adults.
Unsolicited accounts of personal MDMA/Ecstasy use have provided
consistent statements about its effects on social behavior. Some com-
ments have included descriptions of overall improvement in function-
ing, whereas other examples have described psychosocial healing and
relief from symptoms such as anxiety and trauma. Another common
theme reported is improved connectedness to others. Over 250 ac-
counts that were posted in online discussion forums between 2006
and 2011 (e.g., http://wrongplanet.net, http://www.Erowid.org, http://
www.psychforums.com, http://www.bluelight.ru) were reviewed
prior to commencing original data collection for exploratory doctoral
research on the qualitativeMDMA/Ecstasy experiences of autistic adults
(Danforth, 2013).
The majority of the testimonials included descriptions of positive
outcomes. However, robust dialog about potential drawbacks of im-
proper use also has occurred in online forums. The overall impression
presentedwas thatMDMA/Ecstasy can be helpful for some autistic indi-
viduals, attention to appropriate set and setting is crucial for positive
outcomes, and, as with other interventions, MDMA-assisted therapy
might be contraindicated for individuals at risk for potential abuse or
adverse outcomes (e.g., individuals with history of addiction or who
do not have access to sufﬁcient post-session support). As a caveat, the
authors would advise any individual against taking Ecstasy or Molly,
which aremanufactured andmarketed on the illicitmarket and are sub-
ject to rampant drug substitution and often low-quality MDMA.
The dissertationwas published as amixed-methods study to explore
how autistic adults experience the subjective effects of MDMA/Ecstasy
(Danforth, 2013). The purpose of the qualitative componentwas to doc-
ument a comprehensive analysis of emergent themes from interviews
and to identify themes of clinical relevance. In addition, subjects from
13 countries submitted quantitative survey data, including 100
MDMA/Ecstasy-experienced individuals (76% males; 24% females) and
a 50-subject MDMA/Ecstasy-naïve comparison group (54% males; 46%
females). Respondents' ages ranged from 21 to 74 years. The majority
of respondents reported accounts of sustained beneﬁts after MDMA/Ec-
stasy experiences, including improvement of conditions such as trauma
and social anxiety that are common in autistic populations.
Two notable ﬁndings from survey questions about drug effects were
that 91%of respondents reported that they experienced “Increased Feel-
ings of Empathy/Connectedness,” and 86% indicated “Ease of Communi-
cation” as an effect of their MDMA/Ecstasy use. Positive effects (e.g., joy,
openness, enjoying being touched) were reported as more strongly
experienced than negative effects, and no subjects rated anxiety
symptoms in the “strongly experienced” category. A ﬁnding particularly
relevant to treating social anxiety was that 72% of MDMA/Ecstasy-
experienced participants reported “more comfort in social settings,”
and 12% indicated that the effect lasted for two or more years. Another
positive outcome reported was that 78% of the MDMA/Ecstasy-
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effect, and 15% indicated that the effect lasted two years or longer.
A ﬁnding that might have particular relevance to establishing rap-
port with therapists in clinical settings was that 77% of the MDMA/
Ecstasy-experienced group reported that they found it “easier than
usual to talk to others” as an effect of takingMDMA/Ecstasy, and 18% in-
dicated that the effect lasted up to one year or longer. A ﬁnal ﬁnding
about the duration of effects that could have implications for psycho-
therapy for autistic adults was that 22% of the MDMA/Ecstasy-
experienced group reported “increased insight into own thought pro-
cesses” that persisted for two or more years. Despite the researcher's
multifold efforts to encourage subjects to disclose negative outcomes
and to provide balanced accounts of their experiences, therewere no re-
ported moderate or serious, long-term adverse outcomes in the ﬁnal
data set.5. Method
For the present FDA-compliant, IRB-approved pilot investigation of
the effects ofMDMA-assisted therapy on social anxiety in autistic adults,
a placebo-controlled, double-blindmethodology is being employed, uti-
lizing anMDMA dosage in the range of 75mg–125 mg. Twelve subjects
will be screened and enrolled into the study and randomized into two
groups, with one group of eight subjects receiving the experimental
drug (MDMA) and the control group of four subjects receiving an inac-
tive placebo. Both the subject, the clinical treatment team, and Indepen-
dent Rater assessing treatment outcomes are blind to the condition of
treatment. All subjects will receive two separate treatment sessions,
spaced approximately onemonth apart. Participants who receive place-
bo in the ﬁrst treatment phase can return for one or two optional open-
label treatment sessions with MDMA after the blind is broken after six
months of follow-up data collection (Fig. 1).
Subjects receiving MDMA will be divided into two sub-groups, the
ﬁrst group of four subjects receiving 75 mg MDMA at the ﬁrst session
and 100 mg MDMA at the second session. The second sub-group of
four subjects will receive 100 mg MDMA at the ﬁrst session and
125 mg at the second session. The researchers opted for a dose-
ﬁnding regimen due to anecdotal data that suggested that types of sen-
sory hypersensitivity and emotion regulation challenges common with
autismmight indicate a lower optimal dosing range for this population.
Subjects randomized into the placebo condition will receive inactive
placebo at each of the two treatment sessions, but otherwisewill partic-
ipate in the identically structured treatmentmodel and assessment bat-
tery as those receiving the active drug.Fig. 1. Study struct5.1. Screening, eligibility, and preparation
After signing an informed consent, prospective subjects will be
screened into the study based on eligibility established on a number of
diagnostic instruments, including the Structured Clinical Interview for
Diagnoses Axis I Research Version (SCID-I-RV) (First et al., 2012), the
Leibowitz Social Anxiety Scale (LSAS) (Liebowitz et al., 1985) and the
Autism Diagnostic Observation Schedule (ADOS-2) (Bastiaansen et al.,
2011). All subjects must be 21 years or older, have at least two years
of college education or the equivalent, have an autism diagnosis con-
ﬁrmed by an Independent Rater who is certiﬁed based on research reli-
ability, havemoderate to severe symptoms of social anxiety, and be able
to safely discontinue any psychotropic medications they are currently
being prescribed. They must also have healthy cardiovascular function,
as per electrocardiogram and medical history, and not suffer from dia-
betes, glaucoma, seizures, hypertension, liver disease, glaucoma or any
other condition that the investigator or medical monitor believes
might interfere with subject participation and safety in the study. Sub-
jectsmust also beMDMA-naïve andwithout active substance use disor-
ders. Psychiatric exclusion criteria include family history in ﬁrst-degree
relatives of schizophrenia or bipolar I disorder, or subject diagnoses of
active or past psychotic disorder, borderline personality disorder, disso-
ciative identity disorder, eating disorder or active suicidal ideation.
Prior to entry into the study, all subjects will have a physical exami-
nation, EKG and baseline labs drawn formeasurement of plasmaOT, va-
sopressin and cortisol. Baseline performance using The Awareness of
Social Inference Test (TASIT) (McDonald et al., 2006), Emotion Regula-
tion Questionnaire (ERQ) (Gross and John, 2003), Beck Depression In-
ventory (BDI) (Beck et al., 1996), Perceived Stress Scale (PSS) (Cohen
et al., 1983), Interpersonal Reactivity Index (IRI) (Davis, 1980, 1983),
Rosenberg Self-Esteem Scale (RSES) (Rosenberg, 1965), and State-
Trait Anxiety Index (STAI) (Spielberger et al., 1970) will be examined.
The LSAS will be the primary outcome measure.
Prior to the ﬁrst treatment session, all subjects will receive several
preparatory psychotherapy sessions, where the structure of treatment
and range of possible effectswill be discussed, aswill any past or current
salient issues in the subject's life. These preparatory sessions will also
focus on establishing effective rapport between the subject and the
treatment team. Conventional psychodynamic psychotherapy will be
employed only on a limited basis, as this type of approach is not indicat-
ed in general in autistic populations due to mutual interpersonal bar-
riers to the psychotherapeutic alliance with non-autistic therapists
(e.g., Koenig & Levine, 2011; Ramsay et al., 2005). As an alternative, re-
search ﬁndings support mindfulness training in autistic populations. In
Bögels et al., (2008), autistic children and their parents reportedure overview.
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personal goals, self-control, and other measures that contribute to qual-
ity of life after receivingmindfulness training. Consequently, all subjects
will receive core mindfulness skills training as part of their therapy
(Linehan, 1993). An anticipated advantage of this intervention is that
it will provide vocabulary, concepts, and skills that support research
subjects with transitioning into MDMA-inﬂuenced cognitive and affec-
tive states as well as communicating with others during a novel, often
ineffable, altered state of consciousness.
5.2. Treatment sessions
On the days of the two treatment sessions, subjects will arrive at the
clinical research center early in the morning, accompanied by a study
partner, who has previously committed to driving the subject to and
from research sessions, as well as to and from day-after integrative ses-
sions. Ofﬁce visits as well as treatment sessions will take place in a spe-
cially prepared room, which has been designed to minimize sensory
distress (e.g., soft lighting, comfortable seating, minimal noise) and to
resemble a comfortable den-like space more than a clinical setting.
Water intake will be monitored to avoid dehydration or water intoxica-
tion, and optional snacks and a light meal will be made available two
hours after the study drug is administered. The treatment sessions will
be videotaped, though contingent upon subject consent. Prior to exper-
imental drug administration on treatment session days, subjects will
have baseline blood pressure, heart rate and temperature measured,
with hourly repeat measurements following administration of active
drug or placebo for the next seven hours until the conclusion of the
treatment session. Suicidal ideation with the Columbia Suicide Severity
Rating Scale (Posner et al., 2011) and subjective units of distress (SUDs)
will also be assessed during hourly intervals. During the second experi-
mental treatment session, in the late morning, blood will be drawn for
later analyses of OT, vasopressin and cortisol. During the actual drug-
assisted treatment sessions, both structured and unstructured tasks
will be employed, including but not limited to listening to preselected
music, working with art supplies, writing in journals, silent introspec-
tion, and engaging in rapport building interactions with therapists. In
addition, subjects will complete the TASIT, which is an interactive,
video-based assessment of social inference skills. The co-therapists, al-
ways onemale and one female tomanage potential transference during
therapy, will emphasize creating and communicating a setting of safety
and support for the subject during periods of inner focus. More struc-
tured interaction during experimental sessions will focus on challenges
subjects have had with social perception and function.
5.3. Post-session follow-up
The day following each of the two experimental treatment sessions,
subjects will return to the study location for an integrative session,
where safety data will be collected, the content of the previous day's ex-
perience will be examined and methods for adjusting back to daily life
after treatment will be reviewed. Additional in-person integrative psy-
chotherapy sessions will be scheduled at two week intervals for one
month and then again at the six-month follow-up point. Telephone
safety checkswill occur daily for theweek following treatment sessions,
overlapping with the 3–4 days for the drug to be excreted from the
body. Oneday, twoweeks and fourweeks post experimental drug treat-
ment subjects will complete the BDI, STAI, and PSS. At monthly
intervals, between the one-month post-treatment integrative
psychotherapy session and the six-month in-person ﬁnal integrative
psychotherapy session, subjects will complete the BDI, STAI, and PSS
via remote, secure internet connection. In addition to baseline mea-
sures, the LSAS will be conducted the day after experimental treatment
sessions, at two-week intervals for one month and then at the six-
month follow-up. TASITs will be conducted at baseline, the day of the
two experimental treatment sessions, two weeks following each of thetreatments and at the six-month follow-up. A subsequent data analysis
will evaluate outcomes of active drug versus placebo. Additionally, two
post-treatment late-morning blood draws for plasma OT, vasopressin
and cortisol will be conducted one month and six months after experi-
mental treatment.
6. Concluding remarks
Promising ﬁndings from early psychedelics studies with autistic
minors, development of safer clinical research models and methods,
clariﬁcation around optimal set and setting, and an abundance of self-
reported accounts of potential beneﬁts all support the case for initiating
a pilot trial with MDMA-assisted therapy for autistic adults who have
moderate to severe social anxiety.
Researchers gradually and cautiously are exploring a broader range
of potential risks and beneﬁts of MDMA-assisted therapies. In the opin-
ion of the authors, this is the optimal and responsible option for
addressing the public health concerns that have been raised, as well as
to investigate the potential of developing new and novel models for
some psychiatric conditions that are refractory to conventional treat-
ment. Informed understanding of the facts about MDMA, a psychother-
apeutic compound known to enhance prosocial behaviors, is as relevant
to clinicians, researchers, the public, and policymakers now as in any
earlier point in its history.
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